FDA grants supplemental ANDA approval for Glenmark’s Monroe unit
Category: #health  By Dhananjay Punekar  Date: 2018-06-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA grants supplemental ANDA approval for Glenmark’s Monroe unit

Glenmark Pharmaceuticals, a pharma firm based in Mumbai, has received a green signal from U.S. FDA for its drug manufactured at Monroe at North Carolina facility. Incidentally, the approval has been granted for the production of atovaquone and proguanil hydrochloride tablets. These drugs are a generic version of Malarone by GlaxoSmithKline, used for treating malaria, claim sources.

If reports are to be believed, this is the first time that Glenmark has received a supplemental Abbreviated New Drug Application (ANDA) approval from the FDA. Robert Matsuk, President, North America & Global API, Glenmark Pharmaceuticals Ltd, was quoted stating that the approval demonstrates an important achievement for the company’s U.S. business. He further claimed that that the Monroe drug manufacturing site will help Glenmark expand its product line, thereby providing a base for the firm’s future drug approvals.

Sources cite that the Monroe-based unit is the firm’s first drug manufacturing site across the U.S. and had been set up to produce myriad fixed dose drug formulations. For the record, the Indian based pharma company has made investments worth over USD 100 million in the drug manufacturing factory and is planning to expand over the next few years.

FiercePharma has recorded Robert Mastuk’s statement that defends the firm’s investment in Monroe facility and claims that the unit will generate high-quality jobs for the Monroe community, where the company is committed to long-term business expansion.

The North Carolina establishment of Glenmark is expected to manufacture approximately 300-400 million tablets & capsules. The company is also projected to produce 20-25 million vials, pre-filled medical syringes, and 25-30 million ampoules for inhaled formulations.

Authentic reports have claimed that the Mumbai-based drug company has 16 medicine production units across Europe, U.S., and India. The firm has 8 new drug candidates across various therapeutic sectors. Reportedly, during the fourth quarter of FY18, the Indian unit of Glenmark accounted for 27% of the firm’s overall revenue, while the U.S. division contributed approximately 31% towards the total revenue.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...